Company Description
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States.
It is involved in the development of TH104 for the proposed indication of temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with opioids, as well as is in phase 2 study in patients with chronic pruritus in primary biliary cholangitis.
The company also engages in the development of TH023 to treat autoimmune indications; and HS1940, a bispecific biologic against PD-1 and vascular endothelial growth receptor antibody that targets both receptors.
It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics.
The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.
Tharimmune, Inc. was incorporated in 2017 and is based in Red Bank, New Jersey.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jan 12, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Mark Wendland |
Contact Details
Address: 34 Shrewsbury Avenue, Suite 1C Red Bank, New Jersey 07701 United States | |
| Phone | 732-889-3111 |
| Website | tharimmune.com |
Stock Details
| Ticker Symbol | THAR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001861657 |
| CUSIP Number | 432705200 |
| ISIN Number | US4327053090 |
| Employer ID | 84-2642541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark Wendland | Chief Executive Officer |
| Dr. Sireesh Appajosyula Pharm.D. | Interim Chief Financial Officer and Director |
| Vincent LoPriore | Executive Chairman of the Board |
| Mark Toomey | President |
| Dr. Nir Barak M.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 5, 2025 | 424B3 | Prospectus |
| Nov 26, 2025 | EFFECT | Notice of Effectiveness |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 7, 2025 | 8-K | Current Report |
| Nov 7, 2025 | 424B5 | Filing |
| Nov 6, 2025 | 8-K | Current Report |
| Nov 5, 2025 | 8-K | Current Report |
| Nov 3, 2025 | 8-K | Current Report |